FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Immunomedics Inc patents


      
Recent patent applications related to Immunomedics Inc. Immunomedics Inc is listed as an Agent/Assignee. Note: Immunomedics Inc may have other listings under different names/spellings. We're not affiliated with Immunomedics Inc, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics Inc-related inventors


Search recent Press Releases: Immunomedics Inc-related press releases
Count Application # Date Immunomedics Inc patents (updated weekly) - BOOKMARK this page
12015013276805/14/15Anti-pancreatic cancer antibodies
22015012538605/07/15Humanized anti-ceacam5 antibody and uses thereof
32015011127904/23/15Class i anti-cea antibodies and uses thereof
42015009445604/02/15Anthracycline-antibody conjugates for cancer therapy
52015008648203/26/15Dye conjugated peptides for fluorescent imaging
62015005743202/26/15Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
72015003868602/05/15Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
82015001851601/15/15Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
92014037717312/25/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
102014037717712/25/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
112014037728712/25/14Anti-trop-2 antibody-drug conjugates and uses thereof
122014036992712/18/14Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
132014028686009/25/14Immunoconjugates with an intracellularly-cleavable linkage
142014028686109/25/14Rs7 antibodies
152014023420908/21/14Chimeric and humanized anti-histone antibodies
162014022717808/14/14Humanized anti-hla-dr antibodies
172014022717908/14/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
182014022718008/14/14Antibody-sn-38 immunoconjugates with a cl2a linker
192014022854108/14/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
202014021991408/07/14Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
212014021995608/07/14Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
222014021242507/31/14Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
232014019335907/10/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
242014017829406/26/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
252014017006506/19/14Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
262014015427306/05/14Anthracycline-antibody conjugates for cancer therapy
272014014738205/29/14Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
282014014092405/22/14Humanized l243 antibodies
292014012003505/01/14Rs7 antibodies
302014011286404/24/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
312014011286504/24/14Anti-cd19 antibodies
322014010581904/17/14In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
332014009925804/10/14Camptothecin-binding moiety conjugates
342014008683003/27/14Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
352014008683203/27/14Delivery system for cytotoxic drugs by bispecific antibody pretargeting
362014007962903/20/14Class i anti-cea antibodies and uses thereof
372014005806702/27/14Immunoconjugates with an intracellularly-cleavable linkage
382014004463902/13/14Antibody therapy
392014004464002/13/14Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
402014003754302/06/14Anti-pancreatic cancer antibodies
412014003826102/06/14Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
422014003828402/06/14Mammalian cell lines for increasing longevity and protein yield from a cell culture
432014001716801/16/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
442014001719701/16/14Anti-cd19 antibodies
452014000407801/02/14Immunoconjugates with an intracellularly-cleavable linkage
462013031582111/28/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
472013030917711/21/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
482013021656108/22/13Immunoconjugates with an intracellularly-cleavable linkage
492013020935608/15/13Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
502013021104408/15/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
512013017749807/11/13Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
522013017752607/11/13Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
532013017106407/04/13Anti-cd74 immunoconjugates and methods of use
542013017106507/04/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
552013017117607/04/13Anthracycline-antibody conjugates for cancer therapy
562013016421406/27/13Antibody-based depletion of antigen-presenting cells and dendritic cells
572013016478306/27/13Mammalian cell lines for increasing longevity and protein yield from a cell culture
582013015669106/20/13Antibody therapy
592013014278706/06/13Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
602013014329606/06/13Delivery system for cytotoxic drugs by bispecific antibody pretargeting
612013012191305/16/13Anti-cd19 antibodies
622013012347305/16/13Bispecific antibody targeting a complement factor or complement regulatory protein
632013009503404/18/13Anti-cd74 immunoconjugates and methods
642013009045804/11/13Immunoconjugates with an intracellularly-cleavable linkage
652013007818203/28/13Structural variants of antibodies for improved therapeutic characteristics
662013007826303/28/13Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
672013007132003/21/13Immunotherapy of autoimmune disorders using antibodies which target b-cells
682013007140603/21/13Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
692013007265903/21/13Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
702013003986102/14/13Dye conjugated peptides for fluorescent imaging
712013003449202/07/13Class i anti-cea antibodies and uses thereof
722012032856412/27/12Camptothecin-binding moiety conjugates
732012032863412/27/12Immunoconjugates with an intracellularly-cleavable linkage
742012032155312/20/12Ultrafiltration concentration of allotype selected antibodies for small-volume administration
752012028217811/08/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
762012027610011/01/12Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
772012023095309/13/12Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
782012021496908/23/12Methods and compositions for f-18 labeling of proteins, peptides and other molecules
792012019632608/02/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
802012018954207/26/12Anti-cd19 antibodies
812012018347207/19/12Immunotherapy of b-cell malignancies using anti-cd22 antibodies
822012018355007/19/12Therapeutic using a bispecific antibody
832012014908506/14/12Fusion proteins containing recombinant cytotoxic rnases
842012014137206/07/12Rs7 antibodies
852012014137506/07/12Anti-mucin antibodies for early detection and treatment of pancreatic cancer
862012013492005/31/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
872012011455605/10/12Immunotherapy of autoimmune disorders using antibodies which target b-cells
882012010723505/03/12Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
892012008829904/12/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
902012008261704/05/12Immunoconjugates with an intracellularly-cleavable linkage
912012007672703/29/12In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
922012006399303/15/12Therapeutic and diagnostic conjugates for use with multispecific antibodies
932012003979702/16/12Antibody therapy
942012004043102/16/12Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
952012003418502/09/12Anti-cd20 antibodies and fusion proteins therof and methods of use
962011031153112/22/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
972011030563112/15/11Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
982011030006612/08/11Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
992011029351312/01/11Immunoconjugates with an intracellularly-cleavable linkage
1002011028691811/24/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
1012011028080111/17/11Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1022011027470411/10/11Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1032011025605310/20/11Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
1042011024384110/06/11Antibody-based depletion of antigen-presenting cells and dendritic cells
1052011024454610/06/11Internalizing anti-cd74 antibodies and methods of use
1062011023630409/29/11Structural variants of antibodies for improved therapeutic characteristics
1072011023640409/29/11Methods for protein expression in mammalian cells in serum-free medium
1082011022940709/22/11Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1092011022364509/15/11Multivalent carriers of bi-specific antibodies
1102011019502308/11/11Internalizing anti-cd74 antibodies and methods of use
1112011018908508/04/11Antibody therapy
1122011018926808/04/11Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1132011017112607/14/11Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1142011016507207/07/11Detection of early-stage pancreatic adenocarcinoma
1152011016507307/07/11Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1162011011701005/19/11Methods and compositions for administering therapeutic and diagnostic agents
1172011011710505/19/11Method of treating immune disease using b-cell antibodies
1182011011085405/12/11Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1192011007623303/31/11Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1202011007015503/24/11Anti-cd74 immunoconjugates and methods
1212011007015603/24/11Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1222011006465303/17/11Class i anti-cea antibodies and uses thereof
1232011005248903/03/11Anti-cd19 antibodies
1242010031116212/09/10Mammalian cell lines for increasing longevity and protein yield from a cell culture
1252010028490611/11/10Internalizing anti-cd74 antibodies and methods of use
1262010027263610/28/10Anti-cd74 immunoconjugates and methods of use
1272010026649610/21/10Anti-cd74 immunoconjugates and methods of use
1282010026649710/21/10Internalizing anti-cd74 antibodies and methods of use
1292010023377909/16/10Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1302010022688409/09/10Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1312010022117509/02/10Antibody therapy
1322010022117709/02/10Rs7 antibodies
1332010021666208/26/10Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1342010020296108/12/10D-amino acid peptides
1352010019626608/05/10Humanized anti-hla-dr antibodies
1362010019626708/05/10Humanized l243 antibodies
1372010019698908/05/10Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1382010018964107/29/10Novel strategies for improved cancer vaccines
1392010015880206/24/10Chimeric, human and humanized anti-csap monoclonal antibodies
1402010015880306/24/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1412010013662606/03/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1422010010458904/29/10Immunoconjugates with an intracellularly-cleavable linkage
1432010007484003/25/10Anthracycline-antibody conjugates for cancer therapy
1442010006813603/18/10Anti-cd19 antibodies
1452010004054102/18/10Structural variants of antibodies for improved therapeutic characteristics
1462010003473802/11/10Structural variants of antibodies for improved therapeutic characteristics
1472010001504601/21/10Camptothecin-binding moiety conjugates
1482010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1492010000885501/14/10Production and use of novel peptide-based agents with bispecific antibodies
1502010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1512009030458012/10/09Anti-pancreatic cancer antibodies
1522009029903312/03/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1532009029109311/26/09Immunoconjugates with an intracellularly-cleavable linkage
1542009028575211/19/09Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
1552009027464911/05/09Bispecific antibody point mutations for enhancing rate of clearance
1562009025273110/08/09Multivalent carriers of bi-specific antibodies
1572009025317910/08/09Mammalian cell lines for increasing longevity and protein yield from a cell culture
1582009024613010/01/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1592009024613110/01/09Production and use of novel peptide-based agents for use with bi-specific antibodies
1602009024621410/01/09Fusion proteins containing recombinant cytotoxic rnases
1612009023875709/24/09Methods and compositions for administering therapeutic and diagnostic agents
1622009024003709/24/09Humanized antibodies and methods of humanizing antibodies
1632009018597407/23/09Chimeric, human and humanized anti-granulocyte antibodies and methods of use
1642009015516606/18/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1652009015525306/18/09Anti-cd20 antibodies and fusion proteins therof and methods of use
1662009011114304/30/09Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
1672009009259804/09/09Antibody therapy
1682010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1692010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE